Clinical Reasoning
Imprinting, UPD & Cytogenetic Syndromes
Start with the patient and follow the functional pattern to expression state, chromosome structure, parental origin, or developmental mechanism.
The result should earn the mechanism. Parent of origin and copy number come after the clinical pattern has localized the question.
Why this teaches clinical reasoning +
The same phenotype can come from a deletion, uniparental disomy, an imprinting-control defect, or a broader copy-number change. Keeping the final label hidden makes you identify what each test actually answers before you name the syndrome.
Retrieval mode +−
HPI / chief complaint → system / organ / tissue issue → targeted test → outcome of testing → reverse pathophysiology → treatment direction → disease / process.
Think through the patient’s affected systems first. Then ask whether testing is clarifying physiology, chromosome dosage, expression state, or parental origin, and use each result to select the next branch.
How to use the table +
Tap once to revealDouble-tap to blurSelect revealed text to highlightTap a highlight to remove itUse each reasoning note to check why one idea logically follows the next as you move across a row, then shuffle to retrieve the chain out of order.
| Patient presentation HPI / chief complaint | System / organ / tissue issue Where might the problem be? | Testing What question does it answer? | Outcome of testing What does it mean? | Reverse pathophysiology Failure → cause | Treatment direction What follows safely? | Disease / process Reveal this last |
|---|---|---|---|---|---|---|
| A newborn has marked central hypotonia, weak cry, poor suck, and failure to thrive. There is no focal neurologic deficit; over time, developmental delay becomes evident. | The immediate problem is impaired motor tone and feeding coordination: CNS motor control, bulbar or oropharyngeal feeding function, and muscle energy or neuromuscular transmission remain plausible. Examine for a diffuse congenital process rather than assuming isolated prematurity or a local swallowing lesion. | First stabilize feeding and assess common urgent branches as indicated: glucose and electrolytes, thyroid function, infection, cardiopulmonary status, CK, and neurologic evaluation. If these do not explain persistent congenital hypotonia and the developmental pattern, pursue a syndromic genetic evaluation with a parent-of-origin methylation study. | Loss of the normal paternal expression pattern at 15q11–q13 establishes an allele-specific expression failure. It does not identify whether the upstream event is a deletion, maternal UPD, or an imprinting-control defect. | Poor tone and feeding coordination → dysfunction of a shared neurodevelopmental and hypothalamic regulatory program → absence of paternal expression at imprinted 15q11–q13 → paternal deletion, two maternally derived homologs, or failure to establish or maintain the paternal imprint. | Protect feeding and growth first, involve developmental and endocrine teams as the phenotype evolves, and obtain mechanism-specific genetics counseling. | Prader–Willi syndrome — infant presentation |
| A school-age child or adolescent has relentless food-seeking or hyperphagia with rapid weight gain, short stature or altered body composition, delayed or incomplete puberty, learning or behavioral difficulties, and a history that may include early hypotonia or feeding difficulty. | The dominant current failure is hypothalamic and endocrine regulation of satiety, growth, body composition, and pubertal signaling. Learning and behavioral findings add CNS developmental involvement. This is broader than primary lifestyle-associated obesity. | Assess obesity-related and endocrine consequences, review the early developmental history, and use a parent-of-origin methylation study when the congenital, syndromic combination remains convincing. Follow abnormal methylation with copy-number and parental-origin testing. | Absent paternal expression at 15q11–q13 unifies the endocrine and neurodevelopmental pattern. Follow-up distinguishes deletion, maternal UPD, and an imprinting-control defect. | Hyperphagia plus growth and puberty dysregulation → hypothalamic and neurodevelopmental control-system failure → missing paternal expression at an imprinted developmental region → structural loss, abnormal parental origin, or disrupted imprint regulation. | Create a safe food environment and address metabolic, endocrine, sleep, developmental, and behavioral complications with a multidisciplinary team. | Prader–Willi syndrome — school-age/adolescent presentation |
| An infant or young child has severe global developmental delay with disproportionately limited speech, later ataxic or tremulous gait, seizures, microcephaly or slowed head growth, and an unusually excitable or frequently smiling affect. | The pattern localizes to diffuse CNS neurodevelopment: cortical language development, cerebellar or motor coordination, seizure networks, and brain growth are affected together. A behavioral affect alone is never the localization. | Characterize seizures with EEG and assess neurodevelopment, hearing or vision, and neuroimaging or metabolic studies when warranted. If the syndrome pattern supports allele-specific expression failure, use genomic testing including a parent-of-origin methylation study. | Loss of normal maternal expression at 15q11–q13 establishes a parent-specific expression failure. Deletion or duplication testing, parental-marker studies, imprinting-control analysis, and targeted sequencing distinguish the possible causes. | Seizure-prone, poorly coordinated neurodevelopment → insufficient expression of a maternal neuronal developmental program → abnormal allele-specific expression at 15q11–q13, including the neuronal UBE3A program → maternal deletion, paternal UPD, imprinting-control defect, or maternal UBE3A sequence variant. | Direct care toward seizure control, communication, mobility, sleep, developmental therapies, and family counseling while defining the molecular mechanism. | Angelman syndrome |
| A patient has an established neuroendocrine or developmental syndrome with a confirmed 15q11–q13 methylation pattern showing absent paternal expression, but copy-number testing does not show a deletion or duplication. | The phenotype and methylation result have already localized the problem to parent-specific expression at an imprinted region. Normal dosage changes the question to whether two apparently normal copies came from the same parent and carry the same silent program. | Compare the patient’s SNP or microsatellite markers with both parents to determine whether both chromosome 15 homologs came from the mother. If so, assess heterodisomy versus isodisomy. | Maternal-only inheritance of both chromosome 15 homologs explains absent paternal expression despite normal copy number. Isodisomy creates long regions of homozygosity and can reveal a recessive variant. | Meiotic nondisjunction followed by trisomy rescue, or a related rescue or duplication event → two maternally derived chromosome 15 homologs → maternal imprint on both copies → no paternal expression program → the neuroendocrine or developmental phenotype. | Use the inheritance result for counseling and, with isodisomy, consider recessive conditions unmasked by homozygosity. Continue management of documented feeding, endocrine, sleep, and developmental consequences. | Maternal uniparental disomy 15 |
| A patient has a confirmed parent-specific expression abnormality at 15q11–q13 with a compatible developmental phenotype. Copy-number testing is normal, and parental-marker testing does not show uniparental inheritance. | After expression, dosage, and parental-origin studies, the unresolved level is regulation: the machinery that establishes or maintains the parental imprint. | Use targeted analysis of the relevant imprinting-control region. The question is whether the regulatory DNA required to establish or maintain the parental epigenetic mark is altered. | A pathogenic control-region change explains abnormal methylation without a dosage change or UPD. The initiating problem is regulatory control rather than chromosome number or parental origin. | Imprinting-control-region alteration → failure to establish or maintain the correct methylation or chromatin state → inappropriate silencing of a parent-specific developmental program → neurodevelopmental or neuroendocrine phenotype. | Use the confirmed mechanism for recurrence-risk counseling and family studies, while continuing phenotype-directed developmental, neurologic, endocrine, feeding, and sleep support. | Imprinting-control-region defect |
| An infant or child has a heart murmur or hypertension, feeding difficulty or poor growth, developmental delay with a strikingly social or disinhibited behavioral style, characteristic facial features, and may have hypercalcemia or connective-tissue findings. | The presentation spans cardiovascular outflow or arterial function, neurodevelopment and behavior, growth or feeding, and calcium regulation. One isolated cardiac lesion is an incomplete explanation. | Define the cardiovascular problem with four-limb blood pressure assessment and echocardiography; assess calcium and renal function when indicated. If congenital cardiovascular findings coexist with a coherent developmental pattern, use chromosomal microarray. | Echocardiography may show supravalvular aortic stenosis or peripheral pulmonary stenosis. A microarray showing a heterozygous 7q11.23 deletion establishes a contiguous-gene deletion; ELN loss helps explain the arterial component. | Arterial narrowing and elevated resistance → reduced elastic recoil and abnormal arterial-wall architecture → elastin haploinsufficiency within a larger 7q11.23 deletion → combined cardiovascular, developmental, behavioral, and metabolic phenotype. | Follow arterial function, blood pressure, calcium or renal issues, feeding, development, and provide genetic counseling. | Williams syndrome |
| A newborn has a high-pitched, cat-like cry, hypotonia, low birth weight or growth difficulty, feeding problems, microcephaly, and later marked global developmental delay; congenital heart or other structural findings may coexist. | The cry directs attention to laryngeal or airway structure and neurologic control of phonation, while hypotonia, microcephaly, feeding difficulty, and developmental delay indicate a broader CNS developmental process. | First assess airway stability, feeding safety, hearing, neurologic status, and suspected congenital organ involvement. If the congenital developmental pattern persists, use chromosomal microarray; karyotype can clarify an unbalanced rearrangement when warranted. | A microarray showing deletion of the short arm of chromosome 5 establishes a 5p deletion syndrome. Deletion size influences phenotype and whether an inherited rearrangement needs investigation. | Abnormal cry plus global developmental and growth pattern → disrupted laryngeal development and diffuse neurodevelopment → haploinsufficiency of multiple developmental genes from a 5p deletion → variable congenital multisystem phenotype. | Prioritize airway and feeding safety, developmental support, hearing and congenital-anomaly evaluation, and family cytogenetic counseling. | Cri-du-chat syndrome |
| A newborn or child has a conotruncal cardiac defect or murmur, recurrent or unusual infections, hypocalcemic symptoms such as jitteriness, tetany, or seizures, feeding or palatal difficulties, and developmental or behavioral concerns. | The pattern connects cardiac outflow development, thymic or immune function, parathyroid-calcium regulation, and craniofacial or palatal development. Their congenital co-occurrence suggests a shared developmental-field process. | Stabilize acute hypocalcemia and define cardiac anatomy with calcium and PTH studies, ECG as needed, echocardiography, and immune assessment. If the findings form a congenital multisystem pattern, use chromosomal microarray. | Low calcium with inappropriately low PTH supports parathyroid hypoplasia or dysfunction; immune studies may show reduced T-cell number or function. A 22q11.2 deletion on microarray unifies this as a microdeletion syndrome. | Conotruncal, thymic, parathyroid, and palatal abnormalities → disrupted pharyngeal-arch pouch development and neural-crest–linked patterning → 22q11.2 microdeletion, commonly involving TBX1 dosage → variable cardiac, immune, endocrine, and craniofacial phenotype. | Treat urgent hypocalcemia and cardiac or airway issues; assess immune status before live-vaccine decisions, coordinate cardiac, endocrine, ENT, and developmental care, and provide genetic counseling. | DiGeorge syndrome (22q11.2 deletion syndrome) |
Study order
Priority order
Use this only after working through the cases yourself. The sequence is intentionally hidden so recognition does not replace reasoning.
Prader–Willi syndrome — infant presentation → Prader–Willi syndrome — school-age/adolescent presentation → Angelman syndrome → Maternal uniparental disomy 15 → Imprinting-control-region defect → Williams syndrome → Cri-du-chat syndrome → DiGeorge syndrome (22q11.2 deletion syndrome)
For educational use only. This is a study and reasoning tool, not medical advice or a substitute for clinical supervision, diagnosis, or treatment.